rheumatoid arthritis

A drug has been found to reduce the risk of developing rheumatoid arthritis by 60 percent according to a study. The findings suggest significant potential for preventing the autoimmune disease.

The article discusses how fatigue and brain fog in seniors may indicate treatable anemia, the emotional and physical toll of 'transfer trauma' when moving older adults, and an inspiring story of a man creating a backyard oasis after an arthritis diagnosis. It emphasizes recognizing symptoms like weakness and cravings for nonfood items as potential signs of anemia and highlights the importance of managing relocations to avoid health complications.

The article highlights that fatigue and brain fog in seniors may indicate treatable anemia, discusses the emotional and physical toll of 'transfer trauma' during relocations for older adults, and notes that men can develop breast cancer. It also features a Wisconsin man who created a backyard oasis after a severe arthritis diagnosis.

Dennis Nagan, a man from Appleton, Wisconsin, transformed his yard into a wildlife-filled oasis called Memory Lake after being diagnosed with severe rheumatoid arthritis. The space, which includes water, sand, and various animals, serves as a therapeutic retreat for him and his family, including his grandchildren.

A study found that one year of treatment with the immune-targeting drug abatacept delayed rheumatoid arthritis onset by up to four years in high-risk individuals, with benefits persisting after treatment ended. The results suggest rheumatoid arthritis may not be inevitable for those at high risk.

A new depression treatment approach targeting the immune system instead of brain chemicals showed early promise in a small clinical trial. An anti-inflammatory drug used for rheumatoid arthritis reduced depression symptoms, fatigue, anxiety, and improved quality of life in participants.

Sen. John Cornyn questioned AbbVie CEO Richard Gonzalez during a 2019 congressional hearing about the company's 136 patents on Humira, a drug with the same active molecule used to treat multiple conditions. Gonzalez defended the patents as 'innovations,' extending patent protection beyond the original 2016 expiry. The exchange highlights concerns about pharmaceutical companies leveraging patent portfolios to maintain monopolies.